ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Veit J. Scheble; Gregor Scharf; Martin Braun; Christian Ruiz; Susanna Stürm; Karen Petersen; Rudi Beschorner; Alexander Bachmann; Tobias Zellweger; Falko Fend; Glen Kristiansen; Lukas Bubendorf; Nicolas Wernert; Zaki Shaikhibrahim; Sven Perner

doi:10.1007/s00428-012-1270-7

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Veit J. Scheble, Gregor Scharf, Martin Braun, Christian Ruiz, Susanna Stürm, Karen Petersen, Rudi Beschorner, Alexander Bachmann, Tobias Zellweger, Falko Fend, Glen Kristiansen, Lukas Bubendorf, Nicolas Wernert, Zaki Shaikhibrahim, Sven Perner^*

^*Corresponding author for this work

Institute of Pathology

13 Citations (Scopus)

Abstract

Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ ² test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.

Original language	English
Journal	Virchows Archiv
Volume	461
Issue number	2
Pages (from-to)	157-162
Number of pages	6
ISSN	0945-6317
DOIs	https://doi.org/10.1007/s00428-012-1270-7
Publication status	Published - 01.08.2012

Funding

Acknowledgments We thank Christine Beschorner for the exceptional technical support and Veit Scharf for helpful contributions to statistical analyses. This work was supported by a grant of the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG), Emmy-Noether-Program, PE1179/2-1], the Wilhelm-Sander-Stiftung (grant no. 2011.077.1) and the Rudolf-Becker-Foundation to SP, a junior grant of the University Hospital of Tuebingen (fortüne-Programme) to VJS and by a grant of the DFG (WE1104/11-1) and German Cancer Aid (Deutsche Krebshilfe, 107827) to NW.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00428-012-1270-7

Cite this

Scheble, V. J., Scharf, G., Braun, M., Ruiz, C., Stürm, S., Petersen, K., Beschorner, R., Bachmann, A., Zellweger, T., Fend, F., Kristiansen, G., Bubendorf, L., Wernert, N., Shaikhibrahim, Z., & Perner, S. (2012). ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Archiv, 461(2), 157-162. https://doi.org/10.1007/s00428-012-1270-7

@article{da5e91b5ba764f54afa33da4d644e84c,

title = "ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer",

abstract = "Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ 2 test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 \%) than in local recurrent castration-resistant prostate cancer (45 \%). The AR amplification frequencies were 45 and 35 \% in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.",

author = "Scheble, \{Veit J.\} and Gregor Scharf and Martin Braun and Christian Ruiz and Susanna St{\"u}rm and Karen Petersen and Rudi Beschorner and Alexander Bachmann and Tobias Zellweger and Falko Fend and Glen Kristiansen and Lukas Bubendorf and Nicolas Wernert and Zaki Shaikhibrahim and Sven Perner",

year = "2012",

month = aug,

day = "1",

doi = "10.1007/s00428-012-1270-7",

language = "English",

volume = "461",

pages = "157--162",

journal = "Virchows Archiv",

issn = "0945-6317",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

Scheble, VJ, Scharf, G, Braun, M, Ruiz, C, Stürm, S, Petersen, K, Beschorner, R, Bachmann, A, Zellweger, T, Fend, F, Kristiansen, G, Bubendorf, L, Wernert, N, Shaikhibrahim, Z & Perner, S 2012, 'ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer', Virchows Archiv, vol. 461, no. 2, pp. 157-162. https://doi.org/10.1007/s00428-012-1270-7

TY - JOUR

T1 - ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

AU - Scheble, Veit J.

AU - Scharf, Gregor

AU - Braun, Martin

AU - Ruiz, Christian

AU - Stürm, Susanna

AU - Petersen, Karen

AU - Beschorner, Rudi

AU - Bachmann, Alexander

AU - Zellweger, Tobias

AU - Fend, Falko

AU - Kristiansen, Glen

AU - Bubendorf, Lukas

AU - Wernert, Nicolas

AU - Shaikhibrahim, Zaki

AU - Perner, Sven

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ 2 test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.

AB - Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ 2 test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.

UR - https://www.scopus.com/pages/publications/84867400536

U2 - 10.1007/s00428-012-1270-7

DO - 10.1007/s00428-012-1270-7

M3 - Journal articles

C2 - 22767266

AN - SCOPUS:84867400536

SN - 0945-6317

VL - 461

SP - 157

EP - 162

JO - Virchows Archiv

JF - Virchows Archiv

IS - 2

ER -

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Emmy Noether Research Group: TMPRSS2-ERG gene fusion as a new biomarker for prostate cancer patients and development of a urine test for non-invasive diagnosis of prostate cancer with gene fusion

Cite this

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

Emmy Noether Research Group: TMPRSS2-ERG gene fusion as a new biomarker for prostate cancer patients and development of a urine test for non-invasive diagnosis of prostate cancer with gene fusion

Cite this